z-logo
open-access-imgOpen Access
A Covid-19 Patient with Complement-Mediated Coagulopathy and Severe Thrombosis
Author(s) -
Christopher R. Showers,
Gerard J. Nuovo,
Amit Lakhanpal,
Caroline H. Siegel,
Juliet Aizer,
Lauren Elreda,
Alexandra Halevi,
Andrew Lai,
Doruk Erkan,
Cynthia M. Magro
Publication year - 2020
Publication title -
pathobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.941
H-Index - 53
eISSN - 1423-0291
pISSN - 1015-2008
DOI - 10.1159/000512503
Subject(s) - coagulopathy , medicine , thrombosis , covid-19 , antibody , immunology , virology , disease , infectious disease (medical specialty)
We report a patient with severe Covid-19-associated coagulopathy and type 2 diabetes mellitus who tested positive for antiphospholipid antibodies (aPL). Analysis of skin specimens suggested direct SARS-CoV-2 viral-induced and complement-mediated vascular injury and thrombosis, consistent with prior reports. Serial aPL testing demonstrated high levels of anticardiolipin antibodies (aCL) that declined to insignificant levels over a period of 5 weeks. SARS-CoV-2 RNA was detected in nasopharyngeal swab specimens on serial assays performed over the same 5-week period, though it was not detected thereafter. We hypothesize that SARS-CoV-2 viral-induced aPL contributed to severe Covid-19-associated coagulopathy in this patient.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom